Virtus Biotech Clinical Trials ETF
BBC
19 hedge funds and large institutions have $15.7M invested in Virtus Biotech Clinical Trials ETF in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
5.81% less ownership
Funds ownership: 42.8% → 36.99% (-5.8%)
14% less funds holding
Funds holding: 22 → 19 (-3)
25% less capital invested
Capital invested by funds: $20.9M → $15.7M (-$5.18M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$765K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$513K |
| 3 |
Morgan Stanley
New York
|
+$51.2K |
| 4 |
LPL Financial
San Diego,
California
|
+$26.1K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$4.56M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$592K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$488K |
| 4 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
-$212K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$118K |
BBC Hedge Fund Activity: Q2 2021 in Review
19 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2021, worth a combined $15.7M — down 25% from $20.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BBC and 2 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Royal Bank of Canada, adding an estimated $765K. The largest seller was Fulcrum Equity Management, exiting entirely with an estimated $4.56M sold.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2021, down from 22 in Q1 2021.
- Funds reported $15.7M of Virtus Biotech Clinical Trials ETF stock for Q2 2021, down 25% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2021 and 5 closed out, a net change of -3 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2021 was Royal Bank of Canada, an estimated $765K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2021 was Fulcrum Equity Management, an estimated $4.56M sold.
Based on aggregated 13F filings for Q2 2021.